www.regonline.co.uk/Pathology13
Friday, 06 December 2013
The O2, London. SE10 0DX, United Kingdom
This new conference will feature current topics presented by experts in their fields of research and practice. Placed in the context of molecular cellular pathology presentations will explore disease mechanisms, clinical advances and latest technology breakthroughs.
This event has CPD accreditation
Who Should Attend
All who need to be at the leading edge of developments in this area will find this attendance at this conference rewarding. Accordingly, attendance is recommended to students and professionals within the diagnostic and research communities that engage with molecular aspects of cellular pathology.
09:00 – 09:45 Registration
09:45 – 10:00 Introduction by the Chair: Dr Anthony (Tony) Warford, Senior Lecturer in Cellular Pathology, University of Westminster, UK
10:00 – 10:35 Update in the molecular pathology of uveal melanoma
Professor Sarah Coupland, Professor and Honorary Consultant in Pathology, University of Liverpool, UK
Uveal Melanoma (UM), the most common primary intraocular cancer in adults, is fatal in 50% of patients, because of metastatic spread involving the liver. Chemotherapy of metastases has limited success and disseminated disease occurs in most patients <2 years of diagnosis. Clinical, histopathological and genetic risk factors for UM metastasis are documented. UM is characterised by frequent non-random gross chromosomal changes, the most common being monosomy 3, gain of 8q, loss of 1p, gain of 6p and loss of 6q. The first two chromosomal abnormalities in particular are the strongest predictors for metastasis development. The purposes of this presentations are to review: a) described genetic abnormalities of UM, and relate these to hypotheses regarding tumour development and spread; b) current methods used in UM prognostication.
10:35 – 11:10 The modification of proteins by glycosylation: the bitter-sweet tale of breast cancer metastasis
Dr Miriam Dwek, Reader, Dept of Molecular and Applied Biology, School of Life Sciences, University of Westminster, 115 New Cavendish Street, London.
11:10 – 11:40 Speakers’ photo then mid-morning break and trade show/poster viewing
Please try to visit all the exhibition stands during your day at this event. Not only do our sponsors enable Euroscicon to keep the registration fees competitive, but they are also here specifically to talk to you
11:40 – 11.55 Presentation to be confirmed
Promega, UK
11:55 – 12:30 mTOR (Mammalian target of rapamycin) signalling in health and disease
Professor Christopher Proud, Professor of Cellular Regulation at University of Southampton
The mTOR (mammalian target of rapamycin) in a protein kinase that binds partner proteins to form a complex called mTOR complex 1 (mTORC1). The activity of mTORC1 is controlled by many stimuli, including hormones, growth factors and nutrients. In turn, mTORC1 positively regulates diverse anabolic processes in the cell, including protein and ribosome production, gene transcription, and metabolism. mTORC1 plays a key role in regulating both cell growth and proliferation, and is thus important in diseases of excessive cell growth (e.g., cardiac hypertrophy) or proliferation (cancers). mTORC1 signalling is important in many diseases, including many cancers and certain neurological disorders.
12.30 – 12.45 Presentation to be confirmed
12:45 – 13:45 Lunch and trade show/poster viewing
13:45 – 14.00 Presentation to be confirmed
14.00 – 14.35 Understanding the dynamics of liver diseases with particular reference to human cirrhosis
Professor Malcolm Alison DSc, FRCPath: Professor of Stem Cell Biology, Centre of Tumour Biology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, London
14.35 – 15.10 Barrett’s oesophagus
Dr Rebecca Fitzgerald, Principal Investigator, Cambridge Cancer Centre
15.10 – 15.45 The role of digital pathology and image analysis in tissue research and companion diagnostics
Professor Peter Hamilton, Centre for Cancer Research and Cell Biology Queen’s University Belfast
15:45 – 16.10 Afternoon Tea
16:10 – 16.45 Next Generation Molecular Profiling in Clinical Practice
Michael Gandy, Lead BMS/Clinical Services Manager, UCL-Advanced Diagnostics, UK
16:45 – 17:00 Chairman’s summing up
The Deadline for abstract submissions for oral presentation is July 10th 2013
Abstracts for poster presentation only can be submitted up to two weeks before the event
There will be a best poster prize.
You can download the instructions for authors at
www.euroscicon.com/AbstractsForOralAndPosterPresentation.pdf
Keywords: signalling, mTOR, cancer, protein kinase, therapeutic drugs, Ocular melanoma; monosomy 3; BAP1; MLPA; GEP
About the Chair
Anthony (Tony) Warford expertise is in molecular histopathology. He has set up and managed laboratories in the UK health service, academic institutions, biotechnology and Pharmaceutical companies. Technology developments he has spearheaded include the introduction of diagnostic immunohistochemical methods, validation of antibodies for use as biomarkers, production of probes and methods for in situ hybridisation and supervision and interpretation of GLP tissue based safety studies of potential therapeutic antibodies. Concurrently he has championed quality assurance programmes in histopathology and automation of immunohistochemistry coupled with image capture and analysis. He has also run laboratory safety and human bio-banking programmes. He has published in these fields and shared experience with fellow scientists by organising wet workshops, chairing symposia and lecturing in many countries.
About the Speakers
Miriam Dwek, is the Principal Investigator of the Against Breast Cancer Unit at the University of Westminster, currently comprising 6 researchers and 2 research administrators. Her research work continues in the area of Cancer Glycobiology. Most of the work has been focussed on proteins that show alterations in glycosylation in cancer using HPLC, lectin and proteomic technologies with a view to developing blood and urine tests for breast cancer. The aim is to develop strategies for targeting breast cancer and boosting the immune response to carbohydrate antigens. A further aspect of the research is the interplay between diet and lifestyle and outcome following breast cancer
Malcolm Alison DSc, FRCPath: Professor of Stem Cell Biology, Centre of Tumour Biology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, London
Christopher Proud is a biochemist, who obtained his PhD under the direction of Professor Sir Philip Cohen, in Dundee. This sparked his interest in understanding the complex mechanisms whereby hormones and nutrient control mammalian cells. His work focuses on unravelling the events that happen within cells to allow hormones, e.g., insulin to switch on the production of proteins, a key step both for cells to express their genetic information and for cell growth and division. His research aims to understand the normal control of protein synthesis and its role in diseases such as cancer, heart disease and neurological conditions.
Sarah E. Coupland, MBBS, PhD, is a senior pathologist at the Royal Liverpool University Hospital, and Professor and Academic Lead of Pathology at the University of Liverpool. She is the lead pathologist in Ocular Oncology, which receives patients and tumour specimens from all over the world, and she heads a team of nine students and scientists as chair of the Liverpool Ocular Oncology Research Group (www.loorg.org), which she established together with Prof. B Damato. She is the also the lead hematopathologist in the region, Director of the Liverpool Tissue Bank of the Royal Liverpool University Hospital, and Deputy Head of the Dept of Molecular and Clinical Cancer Medicine. Prof. Coupland has given more than 90 invited lectures around the world, with several of these presentations being prestigious keynote lectures. Prof. Coupland has published more than 140 scientific articles, with at least 68 of these as first or senior author, with an H-index of 28. This is in addition to 16 textbook chapters. Her major scientific achievements include devising the first TNM staging system for ocular adnexal lymphomas; developing a novel grading system for malignancy of in situ conjunctival melanomas; revitalizing the European Ophthalmic Oncology Group; and successfully translating molecular typing of uveal melanoma from a research tool into routine clinical practice.
Professor Peter Hamilton s research interests focus on the development and application of new bio-imaging modalities in cancer, cell biology and tissue diagnostics. This includes automated machine vision in histopathology, 3-D visualisation and quantitation of cell and molecular events and gigapixel image processing. In addition he is the Academic lead for the Northern Ireland Virtual Tissue Archive (NIVTA) housed within the Bioimaging Unit. This is a new initiative funded by the HPSS R&D Office, Queen’s University Belfast and supported by Hewlett Packard.
Registration Web Site: www.regonline.co.uk/Pathology13
Post expires at 5:52pm on Saturday December 7th, 2013
Tags: Cancer, mTOR, Ocular melanoma; monosomy 3; BAP1; MLPA; GEP, protein kinase, signalling, therapeutic drugs
Follow Us!